EMA Authorised: Zomarist (vildagliptin;metformin hydrochloride) — Novartis Europharm Limited

View source ↗

Summary

The EMA authorised Zomarist, a fixed-dose combination of vildagliptin and metformin hydrochloride, for treatment of type 2 diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Zomarist (vildagliptin/metformin hydrochloride)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Novartis Europharm Limited. Decision date: 04/12/2025